Pharmacovigilance in tuberculosis: report of an experience in Brazil

Authors

  • Jorge Luiz da Rocha Consultores do Projeto IncoTB / Centro de Referência Professor Hélio Fraga, Escola Nacional de Saúde Pública, Sérgio Arouca, Fundação Oswaldo Cruz (CRPHF/ENSP/Fiocruz), Rio de Janeiro, RJ Author
  • Claudia Hermínia de Lima e Silva Consultores do Projeto IncoTB Author
  • Caroline Silveira Santos Cyriaco Consultores do Projeto IncoTB / Centro de Referência Professor Hélio Fraga, Escola Nacional de Saúde Pública, Sérgio Arouca, Fundação Oswaldo Cruz (CRPHF/ENSP/Fiocruz), Rio de Janeiro, RJ Author
  • Maria Eugênia Carvalhaes Cury Agência Nacional de Vigilância Sanitária (ANVISA), Brasília, DF Author
  • Márcia Gonçalves de Oliveira Agência Nacional de Vigilância Sanitária (ANVISA), Brasília, DF Author
  • Fernanda Simioni Gasparotto Agência Nacional de Vigilância Sanitária (ANVISA), Brasília, DF Author
  • Carolina Souza Penido Agência Nacional de Vigilância Sanitária (ANVISA), Brasília, DF Author
  • Leandro Roberto da Silva Agência Nacional de Vigilância Sanitária (ANVISA), Brasília, DF Author
  • Cristiane Angeli David Programa Nacional de Controle da Tuberculose Author
  • Patricia Bartholomay Programa Nacional de Controle da Tuberculose Author
  • Faber Katsume Johansen Programa Nacional de Controle da Tuberculose Author
  • Fernanda Dockhorn Costa Programa Nacional de Controle da Tuberculose Author
  • Josué Nazareno de Lima Programa Nacional de Controle da Tuberculose Author
  • Draurio Barreira Programa Nacional de Controle da Tuberculose Author
  • Anete Trajman Programa de Pós-graduação em Clínica Médica da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brasil / McGill University, Montreal, Canadá Author

DOI:

https://doi.org/10.3395/2317-269x.00270

Keywords:

Pharmacovigilance, Tuberculosis, Antitubercular Agents, Adverse Drug Reaction Reporting Systems

Abstract

Tuberculosis (TB) treatment frequently causes adverse reactions, because on one hand, it employs at least four drugs and on the other hand, these drugs are often used in association with other drugs, such as antiretroviral and glucose-lowering drugs, that interact with antitubercular agents. The Brazilian National Tuberculosis Control Program and the National Health Surveillance Agency (ANVISA) developed a partnership to implement a pilot pharmacovigilance project to encourage the reporting of adverse reactions to antitubercular agents. Training followed by monitoring visits was conducted by three reference health services for TB treatment. Among the bottlenecks identified, we found limitations in access to the information system (NOTIVISA), slow Internet connection, poor adverse event reporting in medical records, lack of multidisciplinary integration and involvement of managers, and fragility of information flows. As a consequence, technical instructional materials were developed, the NOTIVISA form was improved and shortened, indicators for monitoring notifications were proposed, and information flows were reset. We conclude that the partnership was successful and suggest a similar strategy for other programs. Integration of health teams as well as development of simplified notification tools are challenges to be overcome if pharmacovigilance actions are to be sustainable in the country.

Downloads

Download data is not yet available.

Author Biography

  • Jorge Luiz da Rocha, Consultores do Projeto IncoTB / Centro de Referência Professor Hélio Fraga, Escola Nacional de Saúde Pública, Sérgio Arouca, Fundação Oswaldo Cruz (CRPHF/ENSP/Fiocruz), Rio de Janeiro, RJ
    Médico Pneumologista e Tisiologista, chefe do Ambulatório do Centro de Referência Professor Hélio Fraga/ENSP/FIOCRUZ, Assessor Técnico do Programa Nacional de Controle da Tuberculose

Published

2015-05-29

Issue

Section

Experience report

How to Cite

Pharmacovigilance in tuberculosis: report of an experience in Brazil. (2015). Health Surveillance under Debate: Society, Science & Technology , 3(2), 131-135. https://doi.org/10.3395/2317-269x.00270